Skip to main content
Shanghai Medicilon Inc. logo

Shanghai Medicilon Inc. — Investor Relations & Filings

Ticker · 688202 ISIN · CNE100003NQ8 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 817 across all filing types
Latest filing 2022-12-09 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688202

About Shanghai Medicilon Inc.

https://www.medicilon.com.cn/

Shanghai Medicilon Inc. is a comprehensive contract research organization providing integrated drug discovery and development services to the global pharmaceutical and biotechnology sectors. The company offers a full spectrum of preclinical services, including medicinal chemistry, lead optimization, in vitro and in vivo biology, pharmacology, and drug metabolism and pharmacokinetics (DMPK). Medicilon specializes in safety evaluation and toxicology studies conducted in GLP-compliant facilities to support Investigational New Drug (IND) applications. Its integrated platform facilitates the transition of drug candidates from initial discovery through preclinical development, covering both small molecule drugs and biologics. By leveraging advanced technology and scientific expertise, the company assists clients in accelerating drug development timelines and optimizing research outcomes.

Recent filings

Filing Released Lang Actions
北京金诚同达律师事务所关于上海美迪西生物医药股份有限公司2022年度向特定对象发行A股股票之补充法律意见书（五）
Capital/Financing Update Classification · 95% confidence The document is a detailed legal opinion letter from a law firm regarding a specific issuance of A shares by Shanghai Medicilon Inc. It includes extensive legal review, shareholder information, related party transactions, asset details, tax and subsidy information, and compliance with laws and regulations. The document is titled as a "Supplementary Legal Opinion Letter (Five)" related to the 2022 issuance of shares to specific investors. It is not a financial report, earnings release, or management discussion, but a legal opinion supporting a capital raising event. This fits the category of Capital/Financing Update (CAP), as it relates to the issuance of shares and legal opinions on that financing activity. The document length is substantial and contains substantive content, not just an announcement or certification, so it is not RPA or RNS. Therefore, the best classification is CAP with high confidence.
2022-12-09 Chinese
上海美迪西生物医药股份有限公司2022年度向特定对象发行A股股票募集说明书（注册稿）（修订稿）
Capital/Financing Update Classification · 100% confidence The document is titled as a "募集说明书" which translates to a "Prospectus" or "Offering Circular" for a specific issuance of A shares by Shanghai Medicilon Inc. in 2022. It contains detailed information about the company, its shareholders, control structure, business, and the specifics of the share issuance. The document is lengthy (15,000 characters) and includes detailed disclosures typical of capital raising documents. It is not an annual report, earnings release, or management discussion, but rather a detailed disclosure related to a capital raising event. Therefore, it fits the category of Capital/Financing Update (CAP).
2022-12-09 Chinese
美迪西：关于调整2022年度向特定对象发行A股股票发行数量上限的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Shanghai Medicilon Inc. regarding an adjustment to the maximum number of A shares to be issued to specific investors in 2022. It details the change in the share issuance limit, references prior board and shareholder approvals, and explains the impact of share capital changes on the issuance limit. The document is focused on capital raising activities and changes in the company's capital structure. It is not a full financial report, earnings release, or management discussion, nor is it a regulatory certification or voting result. The content clearly fits the category of a Capital/Financing Update, as it provides an update on the company's fundraising and share issuance plans.
2022-12-09 Chinese
北京金诚同达（上海）律师事务所关于上海美迪西生物医药股份有限公司2022年第二次临时股东大会的法律意见书
Regulatory Filings
2022-12-08 Chinese
美迪西：简式权益变动报告书（陈金章、CHUN-LIN CHEN、MEDICILON INCORPORATED）
Major Shareholding Notification Classification · 95% confidence The document is titled as a "简式权益变动报告书" which translates to a "Simplified Equity Change Report." It details changes in shareholding relationships and actual control of the company Shanghai Medicilon Biopharmaceutical Co., Ltd. It includes information about shareholders, their relationships, shareholding percentages, and agreements affecting control but explicitly states that there is no change in the number of shares held. The document is a formal disclosure of changes in shareholding structure and control relationships, consistent with notifications of major shareholding changes. It is not an annual report, earnings release, or management report. It is not a proxy statement or voting result announcement. It is not a report publication announcement or regulatory filing in the general sense but a specific equity change report. Therefore, the document fits the category of Major Shareholding Notification (MRQ). The document length is substantial (over 11,000 characters), and it contains detailed substantive information about shareholding changes, not just an announcement or certification, so it is not RNS or RPA. Hence, the classification is MRQ with high confidence.
2022-12-08 Chinese
美迪西：简式权益变动报告书（陈建煌）
Major Shareholding Notification Classification · 100% confidence The document is titled as a "简式权益变动报告书" which translates to a "Simplified Equity Change Report." It details the change in equity relationships among shareholders, specifically the termination of a previously existing concerted action agreement among certain shareholders, without any change in the number of shares held. The document includes detailed disclosures about the shareholder involved, the nature of the equity change, and compliance with relevant securities laws and regulations. It is a formal notification of changes in significant share ownership or control relationships, but does not report financial results or other types of corporate filings. This matches the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels or control. The document is about a change in the actual control of the company due to the ending of a concerted action agreement, which is a significant shareholding event. Therefore, the correct classification is MRQ with high confidence.
2022-12-08 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.